Literature DB >> 9352866

Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis.

M Angelico1, L Carli, C Piat, S Gentile, L Capocaccia.   

Abstract

BACKGROUND & AIMS: Isosorbide-5-mononitrate (Is-5-Mn) exerts beneficial hemodynamic effects in portal hypertension, yet the long-term clinical value is uncertain. The aim of this study was to determine the long-term effects of Is-5-Mn vs. propranolol (Pro) on first bleeding, complications, and death in cirrhosis.
METHODS: One hundred eighteen patients included in a previously published randomized trial comparing Is-5-Mn (20 mg three times daily) with Pro were followed up for up to 7 years (range, 2-91 months). Fifty-seven patients received Is-5-Mn and 61 received Pro.
RESULTS: Thirty episodes of first upper bleeding occurred; 16 were in the Is-5-Mn group. Actuarial probability of bleeding did not differ between the two groups. Endoscopic variceal red signs were the only independent predictors of early bleeding. Of the 52 patients who died, 28 were in the Is-5-Mn group. The likelihood of death was greater among patients assigned to Is-5-Mn than to Pro, but only in patients older than 50 years (72% vs. 48% at 6 years; P = 0.006). Child-Pugh score, bleeding, age, and assignment to Is-5-Mn were independent predictors of death. The likelihood of death without bleeding was also higher (P = 0.05) in the Is-5-Mn group.
CONCLUSIONS: Is-5-Mn is as effective as Pro in preventing early bleeding but is associated with higher long-term mortality.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352866     DOI: 10.1053/gast.1997.v113.pm9352866

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

Review 1.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 2.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

Review 3.  Primary prophylaxis of bleeding from esophageal varices in cirrhosis.

Authors:  Carlo Merkel; Sara Montagnese; Piero Amodio
Journal:  J Clin Exp Hepatol       Date:  2013-09-07

4.  Endoscopic management of esophageal varices.

Authors:  Joaquin Poza Cordon; Consuelo Froilan Torres; Aurora Burgos García; Francisco Gea Rodriguez; Jose Manuel Suárez de Parga
Journal:  World J Gastrointest Endosc       Date:  2012-07-16

Review 5.  Current management of portal hypertension.

Authors:  Andrew S Wright; Layton F Rikkers
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

6.  Variceal Hemorrhage.

Authors:  Lisa A. Brandenburger; Fredric G. Regenstein
Journal:  Curr Treat Options Gastroenterol       Date:  2002-02

7.  Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Peter W Angus; Sanjay Saran Baijal; Yogesh Kumar Chawla; Radha Krishna Dhiman; H Janaka de Silva; Saeed Hamid; Shozo Hirota; Ming-Chih Hou; Wasim Jafri; Mobin Khan; Laurentius A Lesmana; Hock F Lui; Veena Malhotra; Hitoshi Maruyama; Debendranath Guha Mazumder; Masao Omata; Ujjal Poddar; Amrinder S Puri; Praveen Sharma; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Hasnain Ali Shah; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2008-09-05       Impact factor: 6.047

8.  Management of Gastrointestinal Bleeding in Children.

Authors:  John M. Peters
Journal:  Curr Treat Options Gastroenterol       Date:  2002-10

Review 9.  Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices.

Authors:  Don C Rockey
Journal:  Curr Gastroenterol Rep       Date:  2006-02

Review 10.  Variceal bleeding : pharmacological treatment and prophylactic strategies.

Authors:  Cándid Villanueva; Joaquim Balanzó
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.